Contact Us    |      Join    |

"The Voice of Oncology in Massachusetts"

New Coding Guidance for Recently Approved Pfizer Oncology Product ELREXFIO (elranatamab-bccm) injection

February 22, 2024 11:12 AM | Katy Monaco (Administrator)

Effective for dates of service on or after April 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection:

J1323- Injection, elranatamab-bcmm, 1 mg

We are respectfully requesting that you update your membership about this important coding change for ELREXFIO (elranatamab-bccm).

Please see full prescribing information including Boxed Warning, HERE.

Thank you in advance for your consideration and assistance. Please contact me directly If you have any questions or need more information.

* Centers for Medicare and Medicaid Services (CMS)

Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Recommendations.


ADDRESS

860 Winter Street, Waltham, MA, 02451

CONTACT US

tel: 781.434.7329

msco@mms.org

Massachusetts Society of Clinical Oncologists ©2024

Powered by Wild Apricot Membership Software